U.S. IPO & Equity Capital Markets Brief 8/31/2026
Coverage: Traditional U.S. operating-company IPOs and consequential ECM transactions of at least $100 million
1. Executive Summary
The week begins with no final price range, no book from which to judge price sensitivity and no qualifying first-day setup. A light calendar may improve attention for the next launch, but it does not by itself establish scarcity.
Aggreko, Bamboo Insurance and Electra Therapeutics became public SEC filers during the past week, adding energy infrastructure, homeowners insurance and late-stage biotechnology to the Q3 queue. None has launched terms.
2. Active Qualifying IPO Calendar
| Issuer | Expected timing | Price range | Shares / offer | Exchange | Underwriters |
|---|---|---|---|---|---|
| No qualifying IPOs | No qualifying deal scheduled | — | — | — | — |
IPO Prophet® rating. No rating is assigned because there is no qualifying launched deal. Ratings and first-day scenarios should wait for shares, range, seller mix and verified roadshow color.
3. Market Structure and First-Day Read-Through
Tradable float. A quiet week can concentrate attention, but the next issuer must create true scarcity through disciplined float and limited secondary supply.
Institutional demand. Public filings show readiness; they do not prove oversubscription, crossover support or low price sensitivity.
Momentum and FOMO. Energy infrastructure and AI-linked power are the strongest themes in the queue, but pricing and the opening auction must confirm excess demand.
Macro timing. Friday’s U.S. employment report is the principal market event and may influence when issuers launch after the holiday.
4. Newly Public Filings
Aggreko (AGKO). Public F-1 filed August 24 for the NYSE. Goldman Sachs, J.P. Morgan and BofA lead. Strong AI/data-center power exposure is supportive; sponsor supply, leverage, valuation and float will determine scarcity.
Bamboo Insurance (BMB). Public S-1 filed August 28 for the NYSE. J.P. Morgan and Morgan Stanley lead. The preliminary offering is entirely secondary, making valuation, catastrophe risk and sponsor overhang central to demand.
Electra Therapeutics (ETRA). Public S-1 filed August 28 for Nasdaq. Jefferies, TD Cowen, Evercore ISI and Cantor lead. The pre-revenue biotech setup will depend on clinical-data credibility, cash runway, crossover support and final float.
5. Q3 ECM Watchlist
The watchlist explicitly distinguishes public registration statements, confidential submissions and an unfiled candidate. Public filers are not described as generic pipeline names.
| Issuer | Verified filing status | Terms / venue | IPO Prophet® focus |
|---|---|---|---|
| Aggreko (AGKO) | Public F-1 filed Aug. 24 | Terms pending; NYSE | AI-power demand, sponsor sell-down, leverage, valuation and float |
| Bamboo Insurance (BMB) | Public S-1 filed Aug. 28 | Terms pending; NYSE | 100% secondary supply, CVC/White Mountains overhang, catastrophe risk and scarcity |
| Electra Therapeutics (ETRA) | Public S-1 filed Aug. 28 | Terms pending; Nasdaq | Registrational-stage data, pre-revenue biotech demand, cash runway and float |
| CoVolt Power (KVLT) | Public S-1 filed Aug. 21 | Terms pending; NYSE | Primary/secondary mix, $3.6B backlog quality, margins and valuation |
| Orion180 Insurance (OIG) | Public S-1 filed Aug. 20 | Terms pending; Nasdaq | Catastrophe exposure, reinsurance economics, control and scarcity |
| Cumberland Farms | Public F-1 filed July 2 | Terms pending | Deal size, defensive demand, leverage and float construction |
| Entrata (ENT) | Public S-1 filed May 28 | Terms pending; NYSE | Software growth, profitability, crossover support and free float |
| Genneia | Public F-1 filed July 2 | Terms pending | Argentina risk, power exposure, valuation and U.S. book depth |
| Holtec Nuclear | Public S-1 filed July 10 | Terms pending | Nuclear demand, project risk, valuation and primary/secondary mix |
| Syntiant | Public S-1 filed July 6; S-1/A July 13 | Terms pending | Physical-AI demand, semiconductor cyclicality and scarcity |
| Tailored Brands | Public S-1 filed July 10 | Terms pending | Sponsor exit, leverage, consumer demand and valuation |
| YPF Energía Eléctrica | Public F-1 filed July 13; F-1/A July 23 | Terms pending; NYSE intended | Argentina risk, utility fundamentals, seller supply and U.S. demand |
| SB Energy | Confidential submission announced; no public S-1 | Terms and venue undisclosed | AI/data-center power narrative, capital intensity, customer concentration and float |
| Anthropic | Confidential submission reported; no public S-1 | Terms and venue undisclosed | Scale, valuation, AI concentration, scarcity and mega-deal absorption |
| OpenAI | Confidential S-1 submitted June 8; no public S-1 | Terms and venue undisclosed | Valuation, governance, primary capital needs, float and systemic demand |
| Nscale | Unfiled pipeline candidate; no public SEC registration | Timing and terms undisclosed | Data-center backlog, financing needs, customer concentration and market capacity |
The next useful signal will be the first terms amendment. IPO Prophet® should then shift from filing readiness to shares, range, seller mix, float, book coverage, account quality, price sensitivity and the opening clearing price.